Emcure Pharmaceuticals is a science-first drug maker that began life in 1981 as a contract manufacturer - a training ground that taught it how to make complex medicines efficiently at scale - and has since built a branded formulations business that ranks among India’s top twelve by domestic sales, while exporting differentiated generics to more than 70 countries. The company deliberately insulated itself from the brutal U.S. generics market by demerging that business in 2021, freeing it to focus on chronic therapies, women’s health, and hard-to-copy complex products elsewhere. The recurring pattern is visible across its history: it picks therapeutic spaces with high clinical need, builds or buys deep scientific capability around a platform - chirality, liposomal injectables, biologics - and then takes those products across geographies through its own front-end teams or exclusive partnerships with global innovators. # Business segments A single branded-pharmaceuticals engine that develops, makes and sells medicines - but it earns its money in two distinct ways: selling branded prescriptions to Indian doctors through a field force of medical representatives, and selling generic and complex products to hospitals and distributors across Europe, Canada and emerging markets. ## 1. India branded formulations: the doctor-driven prescription business **A field force of medical representatives details brands to doctors across India, building prescription loyalty in chronic and women’s health therapies where patients stay on treatment for years.** - **Chronic therapies are the growth anchor** - the share of chronic medicines in the domestic portfolio rose from roughly a quarter in FY20 to over 38% in FY26, because chronic prescriptions repeat and are less sensitive to price competition than acute treatments. - **Women’s health is the flagship franchise** - the company is ranked #2 in gynaecology in India, and its top brand Orofer XT (for anaemia) earns more than INR 200 crore in a country where 57% of women aged 15-49 are anaemic, giving it a large, medically validated patient pool. - **Nineteen of the top twenty brands rank in the top three of their therapy** - brands like Cardace (cardiovascular, >INR 150 Cr), Amaryl (anti-diabetic, >INR 200 Cr) and CLEXANE (>INR 100 Cr) hold commanding positions, which means the sales force is not starting from scratch with doctors but reinforcing established names. - **Exclusive partnerships bring ready-made blockbusters** - instead of building every brand organically, Emcure signed distribution deals with Sanofi for its oral anti-diabetic drugs, with Roche for nephrology and transplant drugs, and with Novo Nordisk to commercialise the weight-management injection Poviztra (semaglutide) as a second brand in India, giving it immediate revenue from globally proven products. - **New specialist verticals are being carved out** - a dedicated dermatology subsidiary, Emcutix, was launched with an ex-Galderma managing director at the helm to target the USD 1.84 Bn skin-health market, while a Super Specialty vertical focuses on renal, oncology and CNS with a pipeline that includes a first-in-India recombinant Asparaginase for paediatric leukaemia. ## 2. International generics and complex products: taking in-house science abroad **Products developed on Emcure’s own R&D platforms - especially complex injectables and biologics - are sold into regulated and emerging markets where the company either has its own front-end or works through local partners.** - **Europe runs on complex injectables** - the business reached INR 1,850 crore in FY26, and a landmark approval made Emcure the first and only generic company to win EU approval for Liposomal Amphotericin B, a difficult-to-make anti-fungal with roughly USD 270 million in innovator sales, which it began launching in select markets in the second half of the year. - **Canada is a top-10 generics player with a pan-national footprint** - the company is the largest Indian firm by prescription in Canada, with roughly 110 products already launched and over 50 more awaiting approval, including eight near-term first generics that would give it a temporary monopoly when launched. - **The UK subsidiary bought a ready-made pipeline** - Tillomed Laboratories acquired the product portfolio of Manx Healthcare for about £19.7 million, gaining access to over 100 product dossiers, more than half of which were not yet commercialised at the time of purchase, so the deal was as much about future launches as current sales. - **Emerging markets are split between ARV and non-ARV** - the antiretroviral business is underpinned by backward integration into key HIV molecules and a royalty-free voluntary licence from Gilead for Lenacapavir, a long-acting injectable covering 120 countries, while the non-ARV side is being built out with the same complex injectables and biosimilars that succeed in regulated markets, such as Tenecteplase and Pegaspargase. - **Roughly 30% of international revenue comes from complex products** - these are medicines that are hard to formulate or manufacture, which means fewer competitors, longer product lifecycles and better pricing power than plain-vanilla generics. # R&D and manufacturing: the platform engine underneath both businesses **Thirteen factories and over 548 scientists work on scalable technology platforms - chirality, liposomal injectables, biologics - that feed differentiated products into both the India and international segments.** - **Platforms, not one-off products** - R&D is organised around reusable technology platforms such as iron-based formulations, high-potency compounds, and biologics made via microbial and mammalian systems, so a breakthrough in one platform can spawn multiple products across different therapies and geographies. - **The new R&D centre was purpose-built for complex dosage forms** - the Emcure Research Centre near Ahmedabad houses 350 professionals working on sustained-release pills, liposomal injections, inhalers and transdermal patches, which are precisely the kinds of products that command higher margins and face fewer generic competitors. - **Manufacturing is vertically integrated and regulator-friendly** - all 13 plants are compliant with major global regulators including USFDA, EU-GMP and Health Canada, and the company has had no regulatory issues at any plant in the past five years, which means it can reliably supply every market it sells into without disruption. - **The biologics subsidiary Gennova is a long-term differentiator** - it was the third company globally to get emergency-use authorisation for an mRNA vaccine and the first to stabilise one at ordinary refrigerator temperature (2-8°C), and it is now using that mRNA platform to develop a Nipah virus vaccine with up to USD 13.38 million in CEPI funding, while also advancing a genetically modified Leishmania vaccine that showed 82.5% efficacy in dogs and has secured its first US-FDA IND for human trials. # Group structure and partners **Emcure operates through a listed parent and a web of wholly-owned subsidiaries - some built, some bought - that house its specialist businesses, while global partnerships with Sanofi, Novo Nordisk, Roche and Gilead give it access to products and markets it could not reach alone.** - **Zuventus Healthcare is now fully owned** - Emcure bought the remaining 20.42% minority stake for INR 7,249 million in cash, completing the transaction by September 2025, which means the full profit of its INR 10,799 million turnover flows to the parent and operational integration can proceed without minority constraints. - **Emcutix Biopharmaceuticals was incorporated in October 2024** as a dedicated dermatology subsidiary, led by the former managing director of Galderma South Asia, giving it specialist leadership from day one rather than trying to build a skin-health business inside the main company. - **The Canadian structure was simplified** - Marcan Pharmaceuticals acquired the remaining stake in Mantra Pharma for CAD 50 million in July 2026, and Mantra had already absorbed Cutimed, a derma-cosmetics company it bought for up to CAD 5.05 million, so the entire Canadian operation now sits under a single chain of control. - **Global innovator partnerships are the distribution backbone** - exclusive deals with Sanofi (oral anti-diabetics and cardiovascular), Novo Nordisk (semaglutide for weight management), Roche (nephrology and transplant) and Gilead (Lenacapavir for HIV in 120 countries) mean Emcure sells products that carry the innovator’s brand equity and clinical data, while it contributes its field force and distribution reach. - **Renewable energy investments secure captive power** - Emcure and Gennova together hold at least 26% of two solar special-purpose vehicles building a combined 26.47 MWp of ground-mounted solar capacity in Solapur and Gujarat, locking in a portion of their electricity costs and insulating manufacturing from grid-price volatility.